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Abstract
This guidance document was prepared on behalf of the International Council for 
Standardization in Haematology (ICSH), by the ADAMTS13 Assay Working Group, 
which comprises an international group of both clinical and laboratory experts. 
The document provides recommendations on best practice for the performance of 
ADAMTS13 assays in clinical laboratories. ADAMTS13 assays support the differen-
tial diagnosis of thrombotic microangiopathies and have utility in the management 
of thrombotic thrombocytopenic purpura (TTP). There are three types of assay: ac-
tivity, antigen and autoantibody/inhibitor assays. Methods for activity assays differ 
in terms of sensitivity, specificity, precision and turnaround time. The most widely 
used assays involve VWF peptide substrates and either chromogenic ELISA or FRET 
techniques, although chemiluminescence assays and rapid screening tests have re-
cently become available. Tests for autoantibodies and inhibitors allow confirmation 
of acquired, immune-mediated TTP, while antigen assays may be useful in congenital 
TTP and as prognostic markers. In this document, we have attempted to describe 
ADAMTS13 assays and the conditions that affect them, as well as: blood collection, 
sample processing, quality control, standardization and clinical utility; recognizing 
that laboratories in different parts of the world have varying levels of sophistication. 
The recommendations are based on expert opinion, published literature and good 
clinical laboratory practice.
K E Y W O R D S
ADAMTS13, haemostasis, thrombosis, VWF
1  | BACKGROUND
ADAMTS13 (A disintegrin and metalloprotease with a thrombo-
spondin type 1 motif, member 13) is a plasma metalloprotease 
which is critically involved in the control of von Willebrand Factor 
(VWF), its major substrate.1 Secretion from the hepatic stellate cell 
is thought to be the main plasma source of ADAMTS13, although 
small quantities also appear to be produced by the vascular endo-
thelium, podocytes in the kidney glomeruli and it may be detect-
able in platelets.2 VWF is released as an ultralarge molecular weight 
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multimeric form (ULVWF), which is rapidly cleaved by ADAMTS13, 
resulting in progressively smaller multimers.1 The high shear stress 
found in small arterioles unravels the globular form of ULVWF so 
that the metalloprotease domain of ADAMTS13 can come into 
close proximity with the cleavage site in the VWF A2 domain, al-
lowing cleavage. The other domains of ADAMTS13 play a role in 
the attachment and unravelling of VWF, while VWF itself induces 
conformational changes in ADAMTS13, making it fully active.3-7
Thrombotic microangiopathies (TMA) are a group of disorders 
characterized by thrombocytopenia and microangiopathic haemo-
lytic anaemia (MAHA) resulting in varying degrees of organ damage; 
they are rare, but potentially life-threatening unless they are rec-
ognized and treated rapidly. They include thrombotic thrombocy-
topenic purpura (TTP) and haemolytic uraemic syndrome (HUS),8,9 
but may also be secondary to cancer, viral infection (eg HIV), organ 
or bone marrow transplantation, pregnancy (preeclampsia/eclamp-
sia or HELLP syndrome), severe hypertension, drugs, autoimmune 
disorders, sepsis and disseminated intravascular coagulation.10-12 
In thrombotic thrombocytopenic purpura (TTP), there is a loss 
of ADAMTS13 function resulting in the prolonged circulation of 
ULVWF, which has an increased platelet binding capacity and may 
participate in platelet aggregate formation in the microcirculation 
with sequestration and consequent thrombocytopenia. Blood flow 
is limited, causing ischaemic organ damage, and haemolysis occurs 
due to red cell mechanical destruction. Elevated levels of indirect 
bilirubin and lactate dehydrogenase are common due to the gross 
haemolysis. Diagnosis is based on the presence of thrombocyto-
penia and MAHA, as well as the clinical history and examination of 
the blood film13; additional laboratory studies are required to distin-
guish between different causes of TMA.
TTP exists in acquired, immune-mediated (iTTP) and congenital 
(cTTP) forms.14 iTTP is caused by the presence of autoantibodies to 
ADAMTS13, which decrease its function or increase ADAMTS13 
clearance from the circulation. These antibodies are heterogeneous, 
varying in epitope specificity and avidity. iTTP can occur at any age, 
mostly in the 3rd-5th decade of life, and is frequently associated 
with infection and pregnancy, but may also occur secondary to a va-
riety of other conditions. Patients with iTTP who enter remission 
may relapse at varying intervals, most recurrences occurring during 
the first year due to the reappearance of the autoantibody, loss of 
ADAMTS13 and development of ULVWF. In cTTP, which usually 
presents in childhood, the loss of ADAMTS13 activity is caused by 
pathogenic genetic ADAMTS13 variants, resulting in decreased syn-
thesis, secretion, or function.
Later onset cTTP may also occur, often during pregnancy. 
ADAMTS13 assays are useful to distinguish TTP from other TMA and, 
in the untreated patient at presentation, a severe deficiency (<10 IU/
dL) of ADAMTS13 activity is diagnostic for TTP.14 ADAMTS13 activ-
ity has been listed as a critical test.15 Plasma levels and function of 
ADAMTS13 are modulated by hepatic stellate cell damage, cytokine 
levels and oxidation (which inhibits ADAMTS13 proteolytic activity 
and makes VWF resistant to cleavage)2; a mild to moderate reduction 
in activity may occur in cardiovascular disease, liver disease, sepsis 
and consumptive coagulopathies, with. Guidance on the diagnosis of 
TTP, management, therapy and prophylaxis are available13,16,17 and 
ICSH has published recommendations on schistocyte enumeration 
in TMA.18
HUS9 may be subdivided into infection-associated HUS (IA-HUS) 
and complement-mediated HUS (CM-HUS, formerly termed atyp-
ical HUS). IA-HUS is typically associated with Shiga toxin-induced 
bloody diarrhoea in children, which is treated with supportive care, 
and in some cases renal dialysis. CM-HUS, more common in adults, 
usually results from defective regulation of the complement system 
and may sometimes show multisystem symptoms similar to TTP, 
making the differential diagnosis difficult. Unlike TTP, ADAMTS13 
levels are usually normal in CM-HUS, although they sometimes show 
a moderate reduction (30-50 IU/dL). ADAMTS13 assays are thus 
pivotal in differentiating TTP and CM-HUS, which require different 
treatments. Plasma exchange (PEX) and immunosuppressive agents 
are typically used for TTP8,13 while PEX and complement inhibition 
(eg with eculizumab) are used in CM-HUS,19 although PEX may be 
used until a firm diagnosis is made.
The aim of this ICSH document is to provide laboratory guidance 
and an up-to-date summary of best practice for the validation, per-
formance, and reporting of ADAMTS13 assays. The consensus rec-
ommendations provided are based on information from peer-review 
publications, the authors' personal experience and expert opinion, 
as well as good clinical laboratory practice.
2  | PRE-ANALY TIC AL VARIABLES
Citrated (0.109 mol/L sodium citrate) platelet-poor plasma is nor-
mally used for ADAMTS13 assays. Samples should be prepared to 
ensure platelet depletion (<10 × 109/L; ie centrifugation at 2000 g 
for 15 minutes). This should be performed at room temperature 
(18-20°C), particularly if other haemostasis assays might be per-
formed, to avoid potential platelet changes and proteolytic acti-
vation. Serum and heparinized plasma have been used and may 
be advantageous in certain types of assay, where high sensitivity 
is required, with less sample dilution, and where citrate chelation 
of divalent cations interferes with the assay. However, laborato-
ries must validate blood collection into alternative anticoagulants 
before clinical application. Plasma or serum samples should be 
rapidly removed from the cells using a plastic transfer pipette, 
avoiding disturbance to the buffy coat and stored in appropriate 
polypropylene containers.
ADAMTS13 is present in serum, but inaccurate activity results 
could potentially occur, due to platelet and leucocyte activation as 
well as ADAMTS13 degradation, by thrombin and other proteases. 
However, this can be effectively mitigated with protease inhibitors. 
It should be noted that ADAMTS13 activity can also vary signifi-
cantly due to other factors, for example changes in assay buffer con-
ditions (pH, ionic strength and surfactants) can affect ADAMTS13 
activity due to allosteric mechanisms.3-6 EDTA plasma cannot be 
used for activity assays, as it irreversibly disrupts the quaternary 
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structure of ADAMTS13, causing false low/absent activity. In cases 
of unexpected absence of ADAMTS13 activity, where results do not 
fit the clinical picture and to exclude pre-analytical variables such 
as incorrect sample type, a prothrombin time or activated partial 
thromboplastin time on the sample can be helpful as grossly pro-
longed times suggest EDTA contamination or serum. Alternatively, 
as EDTA samples have markedly elevated potassium and decreased 
calcium,20 electrolyte analysis showing an abnormal sodium to po-
tassium ratio suggests EDTA anticoagulant.
Blood samples should be collected with minimal stasis and pro-
cessed rapidly to avoid cellular and plasma activation. Any significant 
delays in processing should be recorded and depending on the lab-
oratory policy, added as a comment to the report. Clotted samples 
or those containing clumped platelets are not suitable. Samples that 
are not being assayed on the same day should be stored frozen at 
below −40°C.
If the samples are shipped to another site, dry ice should be 
used to avoid slow thawing during transit and comparable results 
can then be achieved between different laboratories.21 Although 
ADAMTS13 has been shown to have good stability at room tem-
perature,22 some of these studies have employed samples from 
healthy normal subjects and it is not clear whether stability is good 
in all clinical samples, particularly those with critical illness and 
the potential for reduced plasma protease inhibitor levels. Before 
assay, frozen samples should be warmed to 37°C in a water bath 
for 5-10 minutes, until completely thawed and mixed gently to en-
sure that any cryoprecipitate is dissolved. Thawing for longer than 
this is undesirable as ADAMTS13 activity is lost after prolonged 
periods at 37°C.23
Icteric samples may not be suitable for some assay types (see 
specificity section below) due to interference in absorbance mea-
surement or quenching of fluorescence signal.
Haemolysis is frequently seen in patients with TMA, due to 
entrapment and lysis of red cells in the microcirculation. However, 
where it is due to in vitro haemolysis, for example caused by a slow 
blood draw, fresh samples should be obtained. Variable ADAMTS13 
activity may also be obtained in samples with gross lipaemia, al-
though the exact nature of any influence of plasma lipids on activity 
assays has not been investigated and might possibly vary depending 
on the composition of the lipid.
Samples for TTP diagnosis are optimally collected prior to initia-
tion of PEX, although samples collected early in treatment may still 
be informative. It is important that the laboratory has details of the 
type and timing of treatment.
2.1 | Consensus recommendations on sample 
collection and handling for ADAMTS13 assays
• Citrated plasma (centrifuged to ensure platelet depletion) should 
normally be used.
• Heparin plasma or serum samples may be used depending on the 
assay type and if it is validated for these sample types.
• EDTA plasma is not suitable for ADAMTS13 assays.
• Samples should be centrifuged and plasma separated from the 
cells as rapidly as possible after blood collection to avoid in vitro 
changes.
• Unless assays are performed immediately, plasma samples should 
be stored and shipped below-40°C to avoid potential proteolysis.
3  | ADAMTS13 A SSAYS
There are a variety of in-house and commercial methods for 
ADAMTS13 activity, antigen, inhibitors and ADAMTS13 antibody 
assay.
3.1 | Activity assays
The widespread use of ADAMTS13 assays has been limited by the 
rarity of TTP in the general population, technical difficulty of the as-
says and the length of time taken to generate an assay result.24 First 
generation activity assays involved incubation of patient plasma 
with VWF and measurement of residual VWF by multimer electro-
phoresis,25 SDS PAGE and Western Blotting with VWF antibodies,26 
Immunoradiometric assay,27 or ristocetin cofactor assay,28 or colla-
gen binding ELISA (CBA).29
Electrophoretic detection of VWF multimers and analysis by 
ristocetin cofactor assay are difficult, with poor precision. Assays 
based on residual VWF binding to collagen are also time consum-
ing, but the ELISA principle allows higher throughput, with better 
sensitivity and precision. However, there are numerous potential 
sources of error, including the use of denaturing agents that besides 
unravelling VWF could alter ADAMTS13 structure and dissociate 
ADAMTS13 autoantibodies.
Second generation activity assays employ peptide substrates 
based on the ADAMTS13 cleavage site in the VWF A2 domain. 
These are rapid, producing results within a few hours, with high 
throughput and good precision. However, these assays may fail 
to detect certain inherited ADAMTS13 defects, as they measure 
metalloprotease activity independent of exosite interactions 
with other VWF domains. Similar problems can occur where 
ADAMTS13 autoantibodies against these exosites exist. Elevated 
endogenous VWF levels influence some assays, and increased 
bilirubin levels can interfere in fluorescence-based techniques. 
Some of the current activity assays show relatively poor sensi-
tivity, which can be an issue in the clinical management of TTP. 
The key principles of some of the activity assays have been re-
viewed20; they may be divided into assays utilizing full-length 
VWF as substrate and those using peptides or fragments derived 
from VWF. The details of the more popular assays are given in 
Table 1.
The most commonly used peptide substrate assays employ a 73 
amino acid peptide (VWF73), based on the sequence around the 
cleavage site in the VWF A2 domain,30 although some methods use 
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slightly longer peptides, modified sequences or fluorophores.31 The 
peptides may contain: tags to allow their attachment to microtitre 
plates (eg His-tag); attached proteins to allow measurement of in-
tact or cleaved substrate (eg glutathione S-transferase); or have 
fluorophores (eg 2-(N-methylamino)benzoyl group) and quenchers 
(eg 2,4-dinitrophenyl group) attached adjacent to the cleavage site 
in the fluorescence resonance energy transfer (FRET)-based assays. 
In chromogenic activity ELISA methods, substrate cleavage may be 
detected by loss of signal (eg removal of GST), or the increased bind-
ing of monoclonal antibodies against a neo-epitope generated after 
substrate cleavage (eg anti-N10 antibody).32 In FRET-based assays, 
an increased fluorescence signal occurs due to the loss of quenching 
when the peptide is cleaved and the quencher is no longer in close 
proximity to the fluorophore. The activity ELISA has multiple steps 
(incubation, washing, reagent addition, etc.) and many laboratories 
have microplate readers, whereas the FRET assays can be set-up with 
automatic reagent addition, incubation and measurement, minimizing 
hands-on time, although a fluorescence microplate reader is required.
An ADAMTS13 activity assay based on the VWF73 peptide 
and surface-enhanced laser desorption ionization time-of-flight 
TA B L E  1   Some popular clinical laboratory methods for ADAMTS13 activity
Method Performance Calibrant
Diluent; dilution 
factor
VWF substrate 
type
Detection; assay 
type
a CBA29,48,60,76 LLOQ = 5%-6%
Intra-assay CV = 9%
Inter-assay CV < 15%
PNP diluted in assay 
buffer
5 mmol/L Tris/BSA, 
pH 8
1 mmol/L Pefabloc SC
3 mmol/L BaCl2
1.5 mol/L Urea
DF: 12
Full-length 
plasma-
derived VWF
Residual VWF 
binding to collagen, 
chromogenic ELISA
End-point
a FRET30,31,52,77 LLOQ: 1%-3%
Intra-assay CV: NR
Inter-assay CV: ≤6%
PNP diluted in 
ADAMTS13-
inactivated plasma
5 mmol/L Bis-Tris, 
pH 6
1 mmol/L Pefabloc SC
25 mmol/L CaCl2
0.005% Tween-20
DF: 50
VWF73 
substrate
Fluorescence 
change (ex 355 nm, 
em 450/460 nm)
Kinetic
a FRET30,46,48,49,50,78 LLOQ: 3%-5%
Intra-assay CV: 6%
Inter-assay CV: <10%
PNP diluted in assay 
buffer
5 mmol/L Bis-Tris, 
pH 6
1 mmol/L Pefabloc SC
25 mmol/L CaCl2
0.005% Tween-20
DF: 30
VWF-73 
substrate
Fluorescence 
change (ex 340 nm, 
em 450/465 nm)
Kinetic
FRET3 LLOQ = 0.3%
Intra-assay CV = 1.8%
Inter-assay CV = 1.7%
Heparinized PNP 
(minimally diluted 
in assay buffer)
50 mmol/L HEPES, 
pH 7.4
150 mmol/L NaCl
10 mmol/L CaCl2
1 mg/L BSA
0.05% Tween-20 
protease inhibitor 
cocktail and 
1 mmol/L PMSF
DF: 2
rVWF71 
substrate
Fluorescence 
change (ex 638 nm, 
em 658 nm)
Kinetic
FRET48 LLOQ = 5%
Intra-assay CV = NR
Inter-assay 
CV = 5%-18%
Commercial 
calibrant diluted 
in ADAMTS13-
inactivated plasma
Undisclosed 
components
DF:20
VWF86-ALEXA 
substrate
Fluorescence 
change (ex 485 nm, 
em 530 nm)
Kinetic
Chromogenic activity 
ELISA32,35,48,50
LLOQ: 0.3%-3%
Intra-assay CV: ≤5.4%
Inter-assay CV: ≤8%
Commercial 
calibrant diluted in 
assay buffer
Undisclosed 
components
DF:31
VWF73-GST 
substrate
Chromogenic 
ELISA format 
(anti-GST capture; 
HRP conjugated 
anti-N10 
monoclonal Ab to 
detect substrate 
cleavage)
End-point
Abbreviations: Ab, antibody; CV, coefficient of variation; DF, dilution factor; em, emission; ex, excitation; GST, glutathione S-transferase; HRP 
horseradish peroxidase; LLOQ, lower limit of quantitation; NR, not reported; PNP, pooled normal plasma; r, recombinant.
aExact detail varies between laboratories. 
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(SELDI-TOF) mass-spectrometry has also been reported.33 Although 
highly sensitive, instrumentation requirements make this assay im-
practical for clinical diagnostic use in most hospital settings.
More recently, particle-based automated assays have been de-
veloped. An automated chemiluminescence assay utilizes a two-step 
immunoassay involving magnetic particles coated with GST-VWF73 
peptide substrate and chemiluminescent detection based on an isolu-
minol labelled monoclonal antibody that reacts with the cleaved pep-
tide. It is a rapid assay (33 minutes), with good sensitivity and precision, 
but only has a three point calibration curve. Although there were some 
discrepancies compared to FRET-VWF73 and a chromogenic activity 
ELISA, with some samples showing inter-assay disparity at normal and 
high activity, there was a good correlation between the assays and high 
agreement in classifying samples with ADAMTS13 levels below 10 IU/
dL.34-36 Due to the reaction principle, these assays are not affected by 
icterus, lipaemia or plasma turbidity. However, the sample size in two 
of these studies was small and further evaluations may be needed be-
fore their widespread acceptance and regional regulatory bodies may 
require additional verification or validation procedures.
The ionic strength, pH, divalent cation and chloride ion concentra-
tions are critical in ADAMTS13 assays, and all buffers should be fresh 
in order to avoid pH changes and potential bacterial contamination. 
Alternatively, some buffers can be stored for extended periods lyo-
philized, or prepared as stock solutions (eg 10× stock buffers) espe-
cially if filtered with a 0.22 µmol/L membrane. Beside the pH and ionic 
environment, the use of denaturants and differences in sample dilution 
factor between assays might have an impact on the binding kinetics of 
ADAMTS13 and its autoantibodies, so that varying degrees of disso-
ciation could occur in different assay methods.37 Finally, some assays 
utilize heat inactivated normal plasma (treated at 56°C for 30 minutes 
to denature ADAMTS13) as a diluent, to help preserve the ADAMTS13 
environment and allow a linear standard curve.
3.2 | Point of care (POC)/rapid tests
A rapid, semi-quantitative test for ADAMTS13 activity is now com-
mercially available,38 which utilizes a flow-through cartridge and an 
activity ELISA principle, being completed within 30 minutes, without 
the need for specialized instrumentation or personnel. It has four 
indicator points (zero, 10, 40 and 80 IU/dL) and in comparison with 
a chromogenic activity ELISA in 220 patients with suspected TMA, 
showed 88.7% sensitivity, 90.4% specificity and 96.2% negative pre-
dictive value. The method is limited by its subjective visual interpre-
tation and potential for interference by lipids (which might block the 
device membrane), haemolysis and icterus. The test is suitable for 
use in a POC environment as a screening tool and for the negative 
exclusion of TTP. When decreased activity is detected, it should be 
confirmed by bioassay in an accredited laboratory.
3.3 | Agreement/disparity between activity assays
A number of studies21,34,35,39-52 have investigated the precision and 
comparability of different ADAMTS13 activity assays, although many 
of these have involved small sample numbers, limiting their clinical ap-
plicability. In general, these studies show that the various activity as-
says differ in the lower limit of quantification and linear range, while 
there are clear differences for certain clinical sample types, dependent 
on the exact assay comparison. CBA and peptide substrate-based as-
says are certainly disparate for samples from patients with truncated 
or mutant forms of ADAMTS13 in their plasma, although this is not 
surprising due to differences in the substrate length. The degree of dis-
crepancy may vary between different CBA methods. Differences have 
also been noted between methods using the same peptide substrate, 
even in severe ADAMTS13 deficiency (<10 IU/dL). Sample collection 
Variable Likely sources of discrepancy
Calibrant Normal plasma or rADAMTS13
Diluent Inactivated plasma, buffer, pH and ionic strength
Dilution factor Immune complex dissociation (causes falsely increased activity)
Reagents Denaturants may cause Immune complex dissociation37 (causes 
falsely higher activity)
Substrate type Peptide length and sequence (influences sensitivity to defects 
involving the distal ADAMTS13 domains)
Interfering substances Plasma colour (icterus, haemolysis, etc.) may influence FRET 
assays (causing false lower activity), but causative substances 
are washed away in CBA and chromogenic assays54,55
Haemoglobin Increased plasma haemoglobin can protect VWF from 
ADAMTS13 cleavage3,57,58 (reduced activity), but may have 
less effect on peptide substrates (higher values)
Anti-ADAMTS13 specificity Antibody population may affect ADAMTS13 interaction sites 
present on VWF (causing reduced activity), but not smaller 
peptide substrates (which may give higher values)
ADAMTS13 mutants and 
truncated forms
May affect ADAMTS13 interaction sites present on VWF 
(causing reduced activity), but not smaller peptide substrates 
(which may give higher values)
TA B L E  2   Potential sources of 
discrepancy between activity assays
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and handling differences may contribute to these changes as well as a 
variety of in vivo and in vitro factors (Table 2). The results of these stud-
ies emphasize the need for standardization and further assay devel-
opment. When choosing which ADAMTS13 assay to set up, selection 
will depend on local circumstances (including frequency and number 
of samples, required turnaround time, budget, available equipment and 
expertize). It is clear that it is important to use the same ADAMTS13 
assay in a given patient when managing treatment.
3.4 | Standardization and calibration
An International Standard (IS) plasma for ADAMTS13 is available 
(12/252; NIBSC, South Mimms, UK)53 and is calibrated for activity 
and antigen. This should be used as the primary calibrant for com-
mercial calibrants and local assay standards should be traceable to 
the IS, with results being reported as International Units. Irrespective 
of which anticoagulant, or if serum is used, the assay calibrant should 
be of the same type as the sample, for example use pooled citrated 
plasma standard for citrated samples.3 It should be noted that the 
IS calibration is derived from lyophilized citrated plasma and so dis-
crepancy may occur if the test plasma is prepared using a different 
anticoagulant. The IS has not been assessed with modified assays; 
for example minimally diluted plasma and varying ionic strength. In 
the absence of IS availability, results should be reported as percent-
age of pooled normal plasma. Some commercial calibrants are only 
suitable for use in the manufacturer's kit and may give false low or 
high levels when used in other assay techniques, due to additives 
and buffering. Care should be taken with the use of stabilizers (fre-
quently used in lyophilization of plasma), to avoid pH changes and 
alteration of the ionic environment, which can have marked effects 
on ADAMTS13 function.
3.5 | Sensitivity
ADAMTS13 assay sensitivity can be attributed to several factors, in-
cluding the substrate type, assay method, instrument, buffer condi-
tions and volume of plasma. ADAMTS13 has maximal activity at low 
pH (pH 6) and low ionic strength (zero NaCl) as opposed to pH 7.4 
and salt concentrations similar to those in plasma (150 mmol/L NaCl). 
Generally, VWF peptide-based assays are more sensitive than those 
using multimeric VWF digest analysis. The first generation FRET-
based assay sensitivity was limited (~3%-5% of normal ADAMTS13 
activity),30 whereas more recent, optimized FRETS, chromogenic ac-
tivity ELISA and microparticle-based assays have a limit of quantita-
tion of 0.2-0.3 IU/dL (Table 1). Sensitivity at very low ADAMTS13 
levels ≤5 IU/dL for FRET-based assays can be obscured by baseline 
autofluorescence, temperature fluctuations and photobleaching as-
sociated with fluorophores.
New FRET assays, utilizing a rVWF71 polypeptide correspond-
ing to VWF Gln 1599-Arg1668, containing mutations N1610C and 
K1617R, as well as an N-terminal Gly, are more sensitive and appear 
to overcome the problems of plasma colour, icterus and haemolysis 
(see below) by utilizing fluorophores with different absorbance and 
emission wavelengths.3,5
3.6 | Specificity
In assays using full-length VWF, it must be high purity, containing 
all normal multimer sizes and free of ADAMTS13 contamination. 
This may be checked by performing assay blanks and by measuring 
ADAMTS13 antigen. A variety of peptide substrates derived from 
the VWF A2 domain can be used to assay ADAMTS13 activity5; 
their specificity can be checked by a negative control containing 
10 mmol/L EDTA. When performing assays, the operator should be 
aware that many reagent and plasma additives (EDTA, protease in-
hibitors and surfactants) as well as certain therapeutic materials can 
potentially interfere with assay performance, especially the FRET-
based assays.
Bilirubin levels >100 µmol/L (although rarely seen in acute TTP 
plasmas) can reduce ADAMTS13 activity in the FRETS VWF-73 
assay due to fluorescence quenching at the emission wavelength 
(450 nm).54 This results in reduced baseline fluorescence measure-
ment and apparent ADAMTS13 reduction. The CBA and chromo-
genic peptide ELISA are not affected by bilirubin, which is removed 
in the washing stages. However, in vitro studies suggest that un-
conjugated bilirubin may have a direct, dose-dependent inhibitory 
effect on cleavage of both peptidyl and native VWF substrates by 
ADAMTS13.55 The influence of bilirubin may sometimes be reduced 
by using higher sample dilution, but this is limited by ADAMTS13 
activity level and the detection limit. Bilirubin oxidase has been 
employed56 to avoid quenching, but the method has not been fully 
validated for use with clinical samples. Some samples (with no visi-
ble icterus) exhibit low baseline fluorescence in FRET assays, so it is 
likely that certain other substances or therapeutic agents may influ-
ence the assay.
Haemoglobin has been shown to bind specifically to the VWF 
A2 domain and prevent cleavage by ADAMTS13,57,58 using both full-
length VWF and the VWF A2 domain as substrates. The effect of 
haemoglobin on shorter VWF peptide substrates, such as those used 
in the FRETS and chromogenic assays, is unclear. However, 2 g/L Hb 
reduced ADAMTS13 activity by ~10% in a FRETS-rVWF71 assay,3 
which could have a significant impact on patient management.
3.7 | Antigen assays
Immunoblotting procedures and ELISA assays have been used for 
ADAMTS13 antigen measurement and the latter is the method of 
choice in the clinical diagnostic laboratory when an assay is indi-
cated. There are a variety of commercial kits and numerous poly-
clonal and monoclonal antibodies available for assays. The capture 
and detection antibody selection is critical as monoclonal anti-
bodies directed against the central domains of the protein may 
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detect truncated forms and full-length ADAMTS13, while antibod-
ies directed against the C-terminus may underestimate functional 
ADAMTS13 molecules.
3.8 | Antibody and inhibitor assays
ADAMTS13 autoantibody assays demonstrate the presence of spe-
cific immunoglobulins and are detected in iTTP. Depending on the 
ADAMTS13 domain specificity of the immunoglobulins, they may 
or may not inhibit the proteolytic activity. Inhibitory antibodies can 
be demonstrated in mixing tests and Bethesda type assays. Non-
neutralizing antibodies can influence ADAMTS13 survival in the 
circulation and are clinically relevant. Autoantibody assays, where 
available, are therefore preferred.
3.8.1 | Autoantibody assays
Western blotting, immunocapture and ELISA assays for determina-
tion of ADAMTS13 autoantibody levels have been described,59,60 
but ELISA methods for immunoglobulin (Ig) G class autoantibodies 
are most widely used in clinical laboratories. The calibration of these 
assays, their reporting units and cut-off values vary; the results may 
not be interchangeable.
3.8.2 | Inhibitor tests
Patient plasma is heated at 56°C for at least 30 minutes (to inactivate 
ADAMTS13 and other haemostasis proteins, while leaving IgG unaf-
fected), centrifuged to remove any precipitated protein and doubling 
dilutions are incubated with untreated pooled normal plasma (PNP), 
as a source of ADAMTS13, for 1 hour at 37°C. A control comprising 
heat-treated normal control plasma or buffer and untreated PNP is 
incubated in parallel. After incubation, the residual ADAMTS13 ac-
tivity is measured in the patient and control samples. If an IgG inhibi-
tor is present in the patient sample, the ADAMTS13 activity in the 
test sample will be lower than the control. In this case, the incubated 
dilutions of heat-treated patient plasma are assayed to determine 
inhibitor potency in a Bethesda type assay. Some methods do not 
utilize heat treatment and are therefore potentially sensitive to other 
types of inhibitor (eg anti-ADAMTS13 IgM). Anti-ADAMTS13 IgG is 
thought to be the most clinically significant immunoglobulin class in 
acquired TTP and heating makes the mixing test more specific, but 
adds a technical step and prolongs the analytical time. Assays based 
on inhibition of rVWF71 are very sensitive to inhibitory antibodies 
but are not widely used.3
The effects of different incubation temperatures and different 
assays for measuring residual activity have recently been inves-
tigated,23 showing a good correlation between FRET-based and 
CBA-based inhibitor assays, although the pre-incubation at 37°C 
causes a reduction of plasma ADAMTS13 activity when tested in 
the FRET-based assay. A flow-based assay for ADAMTS13 inhibitor 
assessment has also been described.61
The mixing test inhibitor methods are prone to errors because 
of plasma manipulation and dilution of patient plasma with PNP 
limits the sensitivity. Dilution could potentially alter the equilib-
rium between free and bound antibody. Bethesda type assays of 
ADAMTS13 inhibition may be problematic due to the variability 
in antibody epitope specificity, affinity and reaction kinetics be-
tween patients. Standardization and variability were improved 
when minimally diluted plasma and conditions close to physiologic 
were used. FRETS-rVWF71 was ~2.5-fold more sensitive for in-
hibitory autoantibodies than FRETS-VWF73 using recommended 
protocols.3
Sporadic, weak antibodies may sometimes be detected and may 
be absent when a fresh sample is subsequently obtained. When 
antibody concentrations are high, it may be difficult to determine 
an exact antibody level, as the dilution curve may be nonparallel 
with the calibration curve. This can arise for several reasons: in ac-
quired TTP, there are often a variety of antibodies present, directed 
against epitopes on the spacer domain, the thrombospondin-like 
repeats and other domains; these may vary in avidity and concen-
tration, so that each antibody type is more or less pronounced in 
its effect depending on the dilution used; the reaction kinetics may 
vary between antibodies with different specificities and between 
patients; sample dilution may cause antigen:antibody complex 
dissociation.
There is currently no IS or reference material for ADAMTS13 an-
tibody and inhibitor assays, meaning that numerical results are diffi-
cult to compare between different assay types.
4  | VALIDATION OR VERIFIC ATION OF 
A SSAY PERFORMANCE
FRETS assays (which are often used as reference methods in major 
haemostasis laboratories) are mainly developed in-house and 
are not certified by regulatory bodies (in vitro diagnostic device 
registration (CE mark) in the European Union and US Food and 
Drug Administration). Commercial kits including the most widely 
used chromogenic activity ELISA method have regulatory body 
approval in certain countries. Where they do not, or if tests are 
modified (eg use of bilirubin oxidase), they must be considered as a 
laboratory-developed test (LDT). ICSH recognizes that there is no 
universal definition of an LDT and it is therefore the responsibility 
of the individual laboratory/institution to decide whether a test 
system constitutes a LDT and to implement a validation procedure 
meeting their local regulatory requirements. This might include as-
sessment of linear range, sensitivity limits, comparability, and pre-
cision, or require more extensive investigation/documentation.62 
After the validation of assays, a verification phase should be car-
ried out before clinical implementation, to ensure that the assay 
is consistently producing acceptable results. This may be per-
formed by comparison with another laboratory and participation 
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in external quality assurance (EQA) schemes. The uncertainty of 
measurement (UOM) should be estimated by each laboratory to 
aid in the interpretation of borderline results. Long-term internal 
quality control (IQC) data are used at each IQC level, to determine 
the mean and standard deviation (SD), expressed with 95% confi-
dence (±1.96 SD).63 Thus, a sample with 0.20 IU/dL activity and 
SD 0.03 would give UOM ± 0.04 IU/dL, indicating a true value 
between 0.14 and 0.26 IU/dL.
4.1 | Internal quality control, external 
quality assessment
Some commercial kits provide normal and abnormal control samples, 
and these should be run with every batch of tests to provide IQC. If 
these are not available, or if additional IQC is required, local controls 
using aliquots of plasma samples that have previously been assigned 
a potency and an acceptable performance range can be included. 
Ideally, these should have been originally collected in the same way 
as test samples. Performance should be monitored over a range of 
potencies. Commercial control samples should only be used in the 
methods for which they were designed, unless formal validation is 
performed, as differences in the buffer environment may influence 
their performance.
The United Kingdom National External Quality Assessment 
Service, the ECAT Foundation, the College of American Pathologists 
and the North American Specialized Coagulation Laboratory 
Association, all provide external quality assessment studies for 
ADAMTS13 assays, with several proficiency testing surveys each 
year.
4.2 | Criteria for validation of each assay run
A calibration curve should be performed with each batch of tests 
to avoid reagent and analyser variability. Some activity assay meth-
ods may be particularly temperature sensitive. IQC values should 
be within their target range. Test results should be within the linear 
portion of the calibration curve; if they have levels above this range, 
they should be repeated at higher dilution; if below the range, they 
must be reported as less than the lower limit of quantification. In 
kinetic assays, the baseline readings should be checked and very low 
or high values may indicate an analytical problem.
4.3 | Consensus recommendations on assays for 
ADAMTS13, autoantibodies and inhibitors
• Functional FRET-based assays or chromogenic activity ELISA 
methods are recommended as front line assays as they are sensi-
tive, show good precision and are simpler to use, being completed 
in a few hours.
• Rapid point of care assays may have utility as screening methods 
or “out of hours” emergency tests, but there is currently limited 
performance data.
• Every calibrator should be traceable to the International Standard 
Plasma (12/252) for assaying ADAMTS13 activity in citrated 
plasma samples.
• When reporting results: indicate the type of assay performed and 
use the correct units (eg IU/dL) for activity and antigen assays. If 
calibrants traceable to the IS are not available, use percentage of 
pooled normal plasma. State the reference range for the method.
• High and low activity controls should be included in each assay 
run. Do not use commercial controls in methods other than those 
intended for their use.
• Protocols should be validated after any modification.
• If gross icterus interferes in some FRET assay methods, the prob-
lem can sometimes be resolved by assaying at a higher dilution, 
treatment with bilirubin oxidase, or using a chromogenic activity 
ELISA. A comment regarding potential assay interference should 
be added to the laboratory report.
• If artefactual, in vitro haemolysis is likely (eg secondary to difficult 
venipuncture or use of a small gauge needle), fresh blood samples 
should be obtained. If this is not possible, a comment regarding 
potential assay interference should be added to the laboratory 
report.
• Where assay results do not match the clinical picture, or congen-
ital TTP is suspected and ADAMTS13 activity results are normal 
or only show a mild reduction, collagen-binding assays should be 
considered.
• If decreased ADAMTS13 activity (<20 IU/dL) is detected in a new 
patient, an ADAMTS13 antibody assay or inhibitor test should be 
performed. If the results do not match the clinical picture, poten-
tial EDTA contamination should be considered and where possi-
ble, fresh blood samples obtained.
• Wherever possible, use the same ADAMTS13 assay when study-
ing a patient longitudinally to manage treatment.
5  | CLINIC AL UTILIT Y OF A SSAYS
Due to the rarity of TTP, ADAMTS13 assays are not widely per-
formed and remain mainly confined to specialized laboratories. 
However, recent advances in the development of ADAMTS13 assays 
and recognized importance of ADAMTS13 testing in TMA differen-
tial diagnosis indicate that there is an urgent need for a timely and 
reliable ADAMTS13 result for the clinician. Clinical scoring systems 
such as the PLASMIC score64 (platelets <30 × 109/L, creatinine 
<176 µmol/L, international normalized ratio <1.5, mean corpuscular 
volume <90 fL, evidence of haemolysis, no cancer or organ trans-
plantation) may help clinicians decide on the urgency of ADAMTS13 
testing and the likelihood of a positive TTP diagnosis.
When a patient presents with a clinical scenario and blood film of 
suspected TMA (Fig. 1), deficiency of ADAMTS13 activity of <10 IU/dL 
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(and particularly <5 IU/dL) is diagnostic for TTP.8 Levels greater than 
10 IU/dL suggest another diagnosis depending on the clinical circum-
stances and include consideration of HUS (both Shiga toxin or aHUS) 
and secondary TMA.
The turnaround time for ADAMTS13 activity results varies con-
siderably depending on local practice and logistic reasons, so often 
PEX and prednisolone treatment is initiated early while awaiting 
the assay result. However, PEX is less effective in TMA patients 
with ADAMTS13 >10 IU/dL who do not have TTP,11 so timely ac-
cess to an assay avoids the cost, inconvenience and side effects of 
this ongoing, unnecessary intervention. In addition, access to new 
TMA therapies such as caplacizumab (a nanobody that blocks VWF 
binding to platelet glycoprotein Ib)65 and rituximab (an immunosup-
pressant anti-CD20 antibody)66,67 for acquired TTP and eculizumab 
(a C5 complement inhibitor) for CM-HUS68 is further motivation 
for rapid, widely available screening of ADAMTS-13 activity. This 
could be achieved with recently reported automated chemilu-
minescent immunoassay34-36 or rapid POC tests.38 Subsequent 
confirmation of an abnormal result with an ADAMTS13 FRET or 
activity ELISA assay may be required until these newer, rapid as-
says are further validated. Ideally, the first sample should be taken 
prior to initiation of plasma-based therapy to avoid interference of 
donor plasma ADAMTS13 or dilution of the anti-ADAMTS13 au-
toantibody. However, in a series of 18 acquired TTP patients fol-
lowed throughout daily PEX therapy, >75% still showed <10 IU/
dL ADAMTS13 activity immediately before the fourth exchange 
procedure.69
Differentiating between cTTP and iTTP relies upon the detec-
tion or absence of an ADAMTS13 autoantibody or inhibitor.13,70 
The determination of a clinically significant positive IgG antibody 
varies between laboratories depending on the assay and reagents 
used and the limit of normality varies both numerically and in the 
units used. If no significant ADAMTS13 antibody is found, heredi-
tary deficiency of ADAMTS13 is suspected and replacement ther-
apy with plasma or ADAMTS13 containing FVIII concentrates may 
be considered rather than immunosuppression.70 In these cases, 
ADAMTS13 genetic testing is helpful to confirm the diagnosis of 
cTTP.71 ADAMTS13 phenotypic and genetic testing of the proband's 
parents and siblings is suggested to further confirm the hereditary 
nature of TTP, especially for compound heterozygous mutations and 
for genetic counselling.
Precision of the ADAMTS13 activity assay around the 10 IU/dL 
cut-off level and clinical interpretation of the result is still problem-
atic, leading to a wide variation in clinical decisions and management. 
An indeterminate range of between 10 and 20 IU/dL activity neces-
sitates repeat assay, and it is more likely to be significant for TTP 
diagnosis if a high level of ADAMTS13 autoantibody is also detected. 
Interpreting the clinical significance of an isolated ADAMTS13 an-
tibody result is challenging because of the limited data defining 
abnormal levels and arbitrary normal cut-off values depending on 
the laboratory, leading to the misdiagnoses of a detectable but not 
pathological ADAMTS13 antibody. Furthermore, standardization of 
the method and nomenclature of the ADAMTS13 Bethesda assay 
are lacking. Up to 25% of iTTP patients have autoantibodies that do 
not neutralize the ADAMTS13 activity, but they are thought to be 
pathological by removal of ADAMTS13 through an immune complex 
or other clearance mechanism.72
Around 30%-50% of iTTP patients have exacerbation (falling 
platelet count to below the normal range, an increased LDH level 
and the need to restart PEX within 30 days of the last exchange) 
or relapse (falling platelet count below the normal range, with 
or without clinical symptoms, more than 30 days after stopping 
PEX and requiring therapy) with the risk of exacerbation or re-
lapse related to persisting ADAMTS13 deficiency of <10 IU/dL 
and detectable autoantibodies at the end of plasma exchange 
despite a normal platelet count, or during disease remission, 
respectively.60,70,73,74
Frontline rituximab in acute iTTP and pre-emptive rituximab in 
iTTP patients in remission with persisting low ADAMTS13 activity 
have been considered, but its use, particularly in patients with a first 
event is debated as not all iTTP patients experiencing a first event 
will relapse and not all iTTP patients who have a low ADAMTS13 
activity during remission will relapse. Caplacizumab, which should 
ideally be started in the early phase of the acute TTP event for 
maximum benefit, was also shown to prevent exacerbation in iTTP 
patients achieving clinical response, but still presenting severely re-
duced ADAMTS13 activity, supporting its extended use until the un-
derlying autoimmune disease is resolved. Thus, the appropriate use 
of both rituximab and caplacizumab in iTTP demands the availability 
of accurate and timely ADAMTS13 testing.
Mortality is also increased in iTTP patients with the highest IgG 
ADAMTS13 antibody and lowest ADAMTS 13 antigen level,75 per-
haps suggesting increased clearance or immune complex binding of 
F I G U R E  1   ADAMTS13 testing for the diagnosis of TTP and 
other TMA. *Based on clinical assessment including Clinical Gestalt, 
PLASMIC score, laboratory investigation (haemoglobin, platelet 
count, fragments, and creatinine level). †High titre ADAMTS13 
antibody (ELISA) or functional inhibitor of ADAMTS13 activity 
measured by Bethesda assay. CM-HUS, complement mediated 
haemolytic uremic syndrome; IA-HUS, infection associated 
haemolytic uremic syndrome; TMA, thrombotic microangiopathy; 
TTP, thrombotic thrombocytopenic purpura
Clinical suspicion of TMA*
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circulating ADAMTS13 antigen and these patients may especially 
benefit from new therapies. ADAMTS13 antigen levels are not rou-
tinely measured and have little clinical utility in the absence of ac-
tivity assays24; further work is required to understand the clinical 
significance of this finding.
It is apparent there is an urgent need for standardizing 
ADAMTS13 testing for the different clinical situations of the new 
TMA diagnosis, whether it is iTTP, cTTP, CM-HUS, TTP monitoring 
or prediction of TTP relapse.
5.1 | Consensus recommendations on clinical 
utility of assays
• ADAMTS13 activity <10 IU/dL is diagnostic for TTP in patients 
presenting with a clinical scenario and blood film consistent with 
TMA.
• An alternative diagnosis and repeat ADAMTS13 assay should be 
considered in TMA patients presenting with an indeterminate 
range of 10-20 IU/dL ADAMTS13 activity.
• Alternative diagnosis/therapy should be considered in patients 
with an ADAMTS13 activity >10 IU/dL, especially when >20 IU/
dL, as they rarely respond to PEX.
• The overall clinical picture/treatment of the patient should al-
ways be reviewed with close interaction with clinicians. This is 
important to avoid unnecessary tests and to ensure that appro-
priate tests meet clinical needs, especially when non-TTP expert 
clinicians request assays. Clinical scoring systems such as the 
PLASMIC score may assist in providing guidance for the necessity 
of ADAMTS13 testing.
• ADAMTS13 antibody assays should be used to decide whether 
the patient has cTTP or iTTP; definite cTTP diagnosis requires 
ADAMTS13 genetic testing.
• Nomenclature, normal range, reporting units and methodol-
ogy (eg inhibitory and noninhibitory antibodies) need further 
standardization.
• Follow-up ADAMTS13 activity testing is important as persistently 
low levels increase the risk of exacerbation and TTP relapse.
• ADAMTS13 antigen levels are not clinically useful in the absence 
of activity assays, but may prove helpful in predicting mortality 
risk in iTTP patients with high IgG ADAMTS13 antibody level, al-
though further study is needed.
6  | CONCLUSION
Our knowledge concerning ADAMTS13 assays has advanced con-
siderably in recent years, but there are still considerable knowledge 
gaps concerning: the impact of all pre-analytical variables, calibra-
tion of autoantibody assays, the place of epitope-specific assays, and 
which assays to use in different clinical scenarios.
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